Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
Oncology biotech focused on targeted cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers Results expected Sep 2026 (estimated)
- New drug cocktail targets Hard-to-Treat lung cancer mutation Results expected Sep 2026 (estimated)
- Lung cancer drug adagrasib: which dose works best? Results expected Oct 2026 (estimated)
-
New combo aims to outsmart resistant lung cancer
Disease control CompletedThis phase 3 trial tested whether a combination of sitravatinib (a targeted drug) and nivolumab (an immunotherapy) works better than docetaxel (standard chemo) for people with advanced non-squamous non-small cell lung cancer that got worse after platinum chemo and checkpoint inhi…
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Rollover trial tests continued sitravatinib combo for advanced cancers
Disease control CompletedThis study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefi…
Phase 2/3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC